Nicox S.A. (NYSE Euronext Paris: COX) has announced the strengthening of its European and International Operations team with the appointment of three senior executives at Nicox Pharma, its European subsidiary. David Trevor has joined the Company as Vice President, Managing Director UK and Head of the European Sales Force Effectiveness, Davide Buffoni has been appointed Managing Director, Spain, and François Ducret joins Nicox as Director of International Operations.
The Company also announced the expansion of its product pipeline by entering into an exclusive supply and distribution agreement for a range of eye care products with an undisclosed private European pharmaceutical company specialising in ophthalmics.
The strengthening of the European and International Operations team follows the appointment of Philippe Masquida as Executive Vice President, Managing Director of European and International Operations, in April 2012. The team will manage the commercialisation of Nicox ophthalmic products in Europe and other important markets around the world outside North America.
“These appointments mark the first step in the building of our European and International Operations team, and I’m very pleased to welcome David Trevor, Davide Buffoni and François Ducret to Nicox,” said Philippe Masquida, Executive Vice President and Managing Director of European and International Operations of Nicox Pharma. “The strengthening of our team enhances our ability to structure an effective sales force for the five key European markets, as well as identify the best business partners for the distribution of our products in other important markets. Our ambition is to become an international company in the ophthalmic area, and I am confident that the extensive experience of these new members of our senior team will provide a significant boost to our business expansion.”
The team also will focus on key activities to secure AdenoPlus(TM) reimbursement throughout Europe. AdenoPlus(TM), a rapid point-of-care diagnostic test for the differential diagnosis of acute conjunctivitis, is CE-marked and is available for sale by Nicox or its distributors in Europe and other countries. In the US, Nicox commercialises AdenoPlus(TM) to eye care professionals.
In line with its strategy to build a portfolio of innovative and high-growth potential ophthalmic products through targeted partnerships, Nicox also announced it has entered into an exclusive supply and distribution agreement with an undisclosed private European pharmaceutical company for a range of eye care products. The agreement will enable Nicox to rapidly expand its international business and bring new products to the target markets. Nicox expects to launch this family of products directly and through partners from late 2013 onwards. These products have been developed for a major therapeutic class with a differentiated formulation. Under the terms of the agreement, Nicox will have exclusive rights to market, sell and distribute these products in Europe, Middle East and Africa. The agreement does not provide for any upfront payment from Nicox.